Investor Evening

EDX Medical Group PLC

12 July 2024

 

12 July 2024

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Company")

Investor Evening

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, is pleased to announce its participation in "The Pub Test" Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.

The Company's CEO, Dr Mike Hudson, will engage in a conversation designed especially for private investors. This informal setting offers an opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.

Commenting on the event, Dr Mike Hudson, said:

"We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders, share our vision and answer any questions investors may have."

All attendees will have the chance to network over drinks and a buffet.

To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024

ENDS

Contacts:

EDX Medical plc Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International Ramsay Smith Gary McQueen	[phone] [e-mail]  + 44 (0)7834 694609 [e-mail]
IFC Advisory (Investor Relations) Tim Metcalfe Graham Herring	[phone]

About EDX Medical Group

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

www.edxmedical.com

 

END